

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7252536

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CARL BJARTMAR	11/16/2018
MICHAEL SCHILSKY	11/19/2018
FREDERICK ASKARI	11/08/2018
PETER HEDERA	11/12/2018
RECEIVING PARTY DATA	
Name:	WILSON THERAPEUTICS AB
Street Address:	KUNGSGATAN 3
City:	STOCKHOLM
State/Country:	SWEDEN
Postal Code:	111 43
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	16770022
Application Number:	16997928
Application Number:	17182227
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	patents@alexion.com
Correspondent Name:	ALEXION PHARMACEUTICALS, INC.
Address Line 1:	100 COLLEGE STREET
Address Line 4:	NEW HAVEN, CONNECTICUT 06510
ATTORNEY DOCKET NUMBER:	0541 US INV-WILSON AB
NAME OF SUBMITTER:	DARLENE SUAREZ
SIGNATURE:	/DARLENE SUAREZ/
DATE SIGNED:	03/30/2022
Total Attachments: 8	
source=1. 0541 Signed Assignment C. Bjartmar M. Schilsky F. Askari P. Hedera to Wilson Therapeutics	

AB#page1.tif

source=1. 0541 Signed Assignment C. Bjartmar M. Schilsky F. Askari P. Hedera to Wilson Therapeutics

AB#page2.tif

source=1. 0541 Signed Assignment C. Bjartmar M. Schilsky F. Askari P. Hedera to Wilson Therapeutics

AB#page3.tif

source=1. 0541 Signed Assignment C. Bjartmar M. Schilsky F. Askari P. Hedera to Wilson Therapeutics

AB#page4.tif

source=1. 0541 Signed Assignment C. Bjartmar M. Schilsky F. Askari P. Hedera to Wilson Therapeutics

AB#page5.tif

source=1. 0541 Signed Assignment C. Bjartmar M. Schilsky F. Askari P. Hedera to Wilson Therapeutics

AB#page6.tif

source=1. 0541 Signed Assignment C. Bjartmar M. Schilsky F. Askari P. Hedera to Wilson Therapeutics

AB#page7.tif

source=1. 0541 Signed Assignment C. Bjartmar M. Schilsky F. Askari P. Hedera to Wilson Therapeutics

AB#page8.tif

ASSIGNMENT

Carl Bjartmar, Michael Schilsky, Frederick Askari, and Peter Hedera, c/o Wilson Therapeutics AB, Kungsgatan 3, Stockholm, 111 43, Sweden, (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent of the United States, entitled, and which is a:

Patent Application(s)

Application Serial No.: 62/594,184	File Date: December 4, 2017
Application Serial No.: 62/646,553	File Date: March 22, 2018
Application Serial No.: 62/655,568	File Date: April 10, 2018
Application Serial No.: 62/669,095	File Date: May 9, 2018
Application Serial No.: 62/741,313	File Date: October 4, 2018
Application Serial No.: 62/750,595	File Date: October 25, 2018
Application Serial No.:	File Date:
Application Serial No.:	File Date:

Title: **METHODS OF TREATING WILSON DISEASE**

WHEREAS, Wilson Therapeutics AB, a corporation having its principal place of business at Kungsgatan 3, Stockholm, 111 43, Sweden, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified above;
- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;
- (d) any application(s) for patent of the United States or other countries claiming the Invention(s);
- (e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any substitute application(s), division(s), continuation(s), and continuation(s)-in-part;
- (f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and
- (g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.


The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal

representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: 16 Nov. 2018

By: 
Carl Bjartmar

Witness Date: 16 Nov. 2018

Witnessed By: 
Kristian Bobos

Date: _____

By: _____
Michael Schilsky

Witness Date: _____

Witnessed By: _____

Date: _____

By: _____
Frederick Askari

Witness Date: _____

Witnessed By: _____

Date: _____

By: _____
Peter Hedera

Witness Date: _____

Witnessed By: _____


Date: _____

By: _____
Carl Bjartmar

Witness Date: _____

Witnessed By: _____

Date: 11/19/2018

By: 
Michael Schilsky

Witness Date: 11/19/18

Witnessed By: 
Donna Christensen

Date: _____

By: _____
Frederick Askari

Witness Date: _____

Witnessed By: _____

Date: _____

By: _____
Peter Hedera

Witness Date: _____

Witnessed By: _____

Date: _____

By: _____
Carl Bjartmar


Witness Date: _____

Witnessed By: _____


Date: _____

By: _____
Michael Schilsky

Witness Date: 8 Nov 2018

Witnessed By: _____


Date: 8 Nov 2018

By: _____

Frederick Askari

Witness Date: _____

Witnessed By: _____

Date: _____

By: _____
Peter Hedera

Witness Date: _____

Witnessed By: _____

Date: _____

By: _____
Carl Bjartmar

Witness Date: _____

Witnessed By: _____

Date: _____

By: _____
Michael Schilsky

Witness Date: _____

Witnessed By: _____


Date: _____

By: _____
Frederick Askari

Witness Date: _____

Witnessed By: _____

Date: NOVEMBER 12, 2018


By: _____

Peter Hedera

Witness Date: 11/12/18

Witnessed By: Rosemary Madill
(Rosemary Madill)

For and on behalf of ASSIGNEE:

Date: NOV. 19, 2018

By: 
Wilson Therapeutics AB

Witness Date: 11/19/2018

Witnessed By: 